

Characteristics of the whole cohort

Study group	N	HC 78	PD 76	iRBD 21
Demographics				
Male/female (% male)		46/32 (59%)	50/26 (66%)	12/9 (57%)
age, years [mean +/- standard deviation]		68.45 +/- 6.71	68.04 +/- 9.7	66.14 +/- 9.93
Anthropometrics				
weight, kg [mean +/- standard deviation]		80.15 +/- 16.02	83.68 +/- 15.52	78.01 +/- 14.28
height, cm [mean +/- standard deviation]		173.26 +/- 8.84	171.4 +/- 9.66	172.38 +/- 10.05
BMI, kg/(m*m) [mean +/- standard deviation]		26.54 +/- 4.07	28.46 +/- 4.52	26.15 +/- 3.44
Motor Symptoms				
Hoehn and Yahr staging [mean +/- standard deviation]		0 +/- 0	2.13 +/- 0.8	0.05 +/- 0.22
MDS-UPDRS II, sum [mean +/- standard deviation]		1.47 +/- 2.04	13.15 +/- 7.43	3.19 +/- 2.98
MDS-UPDRS III, sum [mean +/- standard deviation]		1.54 +/- 2.8	29.69 +/- 13.58	3.76 +/- 3.24
MDS-UPDRS IV, sum [mean +/- standard deviation]		0 +/- 0	1.06 +/- 1.81	0 +/- 0
MDS-UPDRS, sum [mean +/- standard deviation]		8.47 +/- 7.76	55.62 +/- 24.84	18.81 +/- 9.35
Non-motor symptoms				
MDS-UPDRS I, sum [mean +/- standard deviation]		5.46 +/- 4.3	11.72 +/- 7.22	11.86 +/- 6
MDS-UPDRS anxiety (Question I.4) [mean +/- standard deviation]		0.23 +/- 0.53	0.67 +/- 0.84	1.05 +/- 0.97
MDS-UPDRS pain (Question I.9) [mean +/- standard deviation]		0.69 +/- 0.83	1.28 +/- 1.12	0.9 +/- 0.7
MDS-UPDRS constipation (Question I.11) [mean +/- standard deviation]		0.27 +/- 0.7	1.23 +/- 1.13	0.95 +/- 1.2
Scopa-AUT, sum [mean +/- standard deviation]		8.37 +/- 5.67	13.09 +/- 7.09	12.38 +/- 5.45
Scopa-AUT gastrointestinal part (Questions 1-7), sum [mean +/- standard deviation]		0.91 +/- 1.11	3.18 +/- 2.36	3 +/- 1.97
			often:4 (5%); regularly:2 (3%); sometimes:25 (34%); never:43 (58%);	often:1 (5%); regularly:1 (5%); sometimes:9 (43%); never:10 (48%);
Scopa-AUT constipation (Question 5)		never:71 (91%)	2 n.d.	never:10 (48%);
NMS-Quest constipation (Question 5), yes/no (%)		9/69 (12%)	38/38 (50%)	8/13 (38%)
Non-motor symptom assessment scale (NMSS) constipation (Question 21, strength*frequency) [mean +/- standard deviation]		0.04 +/- 0.25	0.45 +/- 1.52	0.67 +/- 1.43
constipation by interview, N (%)		1 (1%)	15 (20%)	n.d.
other GI dysfunction by interview, N (%)		17 (22%)	24 (32%)	n.d.
Beck depression inventory (BDI), sum [mean +/- standard deviation]		3.71 +/- 4.47	7.35 +/- 5.92	6.79 +/- 5.55
Geriatric Depression Scale (GDS), sum [mean +/- standard deviation]		1.34 +/- 2.2	2.55 +/- 2.61	2.62 +/- 2.36
Epworth Sleepiness Scale (ESS), sum [mean +/- standard deviation]		6.02 +/- 3.69	7.86 +/- 3.84	9.5 +/- 4.36
Mini-Mental-State-Examination (MMSE), total score [mean +/- standard deviation]		28.71 +/- 1.53	27.72 +/- 2.35	28.67 +/- 0.86
Montreal Cognitive Assessment (MoCa), total score [mean +/- standard deviation]		26.1 +/- 2.73	24.32 +/- 4.2	23.81 +/- 3.2
Montgomery-Asberg Depression Rating Scale (MADRS), sum [mean +/- standard deviation]		1.89 +/- 5.05	2.79 +/- 3.78	5.24 +/- 6.14
RBD by polysomnography, N		0	40; 6 n.d.	21
Smell identification test (by 16 item Sniffin Sticks) [mean +/- standard deviation]		11.81 +/- 2.59	5.91 +/- 3.45	6.4 +/- 3.93
Intake of PD medication				
Azilect, N (%)		0 (0%)	50 (66%)	0 (0%)
any MAO-B inhibitors, N (%)		0 (0%)	52 (68%)	0 (0%)
Levodopa, N (%)		0 (0%)	66, (87%)	0 (0%)
L-Dopa agonists, N (%)		0 (0%)	52 (68%)	0 (0%)
COMT inhibitors, N (%)		0 (0%)	4 (5%)	0 (0%)
OTHER: macrogol intake, N (%)		1 (1%)	8 (11%)	0 (0%)
Medical history				
depression, N (%)		11 (14%)	7 (9%)	6 (29%)
anxiety, N (%)		2 (3%)	4 (5%)	3, 1 n.d. (15%)
sleep apnoe, N (%)		8 (10%)	2 (3%)	3 (14%)
periodic limb movement disorder, N (%)		0 (0%)	1 (1%)	1 (5%)
hypertension, N (%)		36 (46%)	43 (56%)	10 (48%)
hyperlipidemia, N (%)		46 (59%)	31 (41%)	7 (33%)
diabetes mellitus, N (%)		4 (5%)	6 (8%)	3 (14%)
osteoarthritis, N (%)		37 (47%)	19 (25%)	11 (52%)
rheumatoid arthritis, N (%)		1 (1%)	6 (8%)	0 (0%)
coronary artery disease, N (%)		2 (3%)	8 (11%)	2 (10%)
congestive heart disease, N (%)		2 (3%)	3 (4%)	1 (5%)
hypothyroidism, N (%)		7 (9%)	7 (9%)	3 (14%)
asthma/COPD, N (%)		9 (12%)	6 (8%)	5 (24%)
cancer, N (%)		4 (5%)	5 (7%)	0 (0%)
antidepressant intake, N (%)		5, 1 n.d. (6%)	5 (7%)	0 (0%)
current diabetes and/or metformin intake, N (%)		6 (8%)	7 (9%)	3 (14%)
metformin intake, N (%)		3 (4%)	4 (5%)	3 (14%)

Characteristics of the cohort with nasal wash samples

Study group		HC 65	PD 70	iRBD 12
Demographics	N			
	Male/female (% male)	36/29 (55%)	47/23 (67%)	7/5 (58%)
	age, years [mean +/- standard deviation]	68.32 +/- 6.28	68.14 +/- 10.06	68 +/- 7.32
Anthropometrics				
	weight, kg [mean +/- standard deviation]	80.31 +/- 16.36	83.59 +/- 15.58	79.54 +/- 16.14
	height, cm [mean +/- standard deviation]	172.89 +/- 8.56	171.64 +/- 9.69	172.17 +/- 10.94
	BMI, kg/(m*m) [mean +/- standard deviation]	26.71 +/- 4.26	28.34 +/- 4.44	26.65 +/- 3.48
Motor Symptoms				
	Hoehn and Yahr staging [mean +/- standard deviation]	0 +/- 0	2.16 +/- 0.82	0.08 +/- 0.29
	MDS-UPDRS II, sum [mean +/- standard deviation]	1.45 +/- 1.93	13.54 +/- 7.56	3.08 +/- 3.09
	MDS-UPDRS III, sum [mean +/- standard deviation]	1.62 +/- 2.72	29.99 +/- 13.91	3.83 +/- 3.38
	MDS-UPDRS IV, sum [mean +/- standard deviation]	0 +/- 0	1.12 +/- 1.87	0 +/- 0
	MDS-UPDRS, sum [mean +/- standard deviation]	8.6 +/- 7.75	56.35 +/- 25.5	17.17 +/- 9.79
Non-motor symptoms				
	MDS-UPDRS I, sum [mean +/- standard deviation]	5.54 +/- 4.49	11.71 +/- 7.36	10.25 +/- 5.03
	MDS-UPDRS anxiety (Question I.4) [mean +/- standard deviation]	0.28 +/- 0.57	0.64 +/- 0.82	0.92 +/- 1
	MDS-UPDRS pain (Question I.9) [mean +/- standard deviation]	0.68 +/- 0.85	1.26 +/- 1.13	0.83 +/- 0.72
	MDS-UPDRS constipation (Question I.11) [mean +/- standard deviation]	0.31 +/- 0.75	1.26 +/- 1.13	0.5 +/- 0.9
	Scopa-AUT, sum [mean +/- standard deviation]	8.72 +/- 5.67	13.05 +/- 7.29	10.42 +/- 4.72
	Scopa-AUT gastrointestinal part (Questions 1-7), sum [mean +/- standard deviation]	0.98 +/- 1.17	3.14 +/- 2.35	2.08 +/- 1.51
			often:4 (6%); regularly:1 (1%); sometimes:25 (37%);	
		often:2 (3%); sometimes:4 (6%); never:59 (91%)	never:38 (56%); 2 n.d.	sometimes:4 (33%); never:8 (67%);
	Scopa-AUT constipation (Question 5)	9/56 (16%)	36/34 (51%)	3/9 (25%)
	NMS-Quest constipation (Question 5), yes/no (%)	0.05 +/- 0.28	0.49 +/- 1.58	0.67 +/- 1.56
Non-motor symptom assessment scale (NMSS) constipation (Question 21, strength*frequency) [mean +/- standard deviation]				
	constipation by interview, N (%)	1 (2%)	13 (19%)	n.d.
	other GI dysfunction by interview, N (%)	16 (25%)	23 (33%)	n.d.
	Beck depression inventory (BDI), sum [mean +/- standard deviation]	3.89 +/- 4.77	7.17 +/- 5.7	5.25 +/- 4.64
	Geriatric Depression Scale (GDS), sum [mean +/- standard deviation]	1.44 +/- 2.35	2.55 +/- 2.67	1.76 +/- 1.43
	Epworth Sleepiness Scale (ESS), sum [mean +/- standard deviation]	6.15 +/- 3.83	7.72 +/- 3.71	n.d.
	Mini-Mental-State-Examination (MMSE), total score [mean +/- standard deviation]	28.71 +/- 1.53	27.72 +/- 2.35	28.67 +/- 0.86
	Montreal Cognitive Assessment (MoCa), total score [mean +/- standard deviation]	26.02 +/- 2.48	24.21 +/- 4.29	23.33 +/- 3.68
	Montgomery-Åsberg Depression Rating Scale (MADRS), sum [mean +/- standard deviation]	1.97 +/- 5.46	2.74 +/- 3.66	3.25 +/- 3.19
	RBD by polysomnography, N	0	37; 5 n.d.	12
	Smell identification test (by 16 item Sniffin Sticks) [mean +/- standard deviation]	11.88 +/- 2.56	5.8 +/- 3.52	7 +/- 3.22
Intake of PD medication				
	Azilect, N (%)	0 (0%)	44 (63%)	0 (0%)
	any MAO-B inhibitors, N (%)	0 (0%)	46 (66%)	0 (0%)
	Levodopa, N (%)	0 (0%)	62, (89%)	0 (0%)
	L-Dopa agonists, N (%)	0 (0%)	46 (66%)	0 (0%)
	COMT inhibitors, N (%)	0 (0%)	4 (6%)	0 (0%)
	OTHER: macrogol intake, N (%)	1 (2%)	7 (10%)	0 (0%)
Medical history				
	depression, N (%)	11 (17%)	7 (10%)	1 (8%)
	anxiety, N (%)	2 (3%)	4 (6%)	0, 1 n.d. (0%)
	sleep apnoe, N (%)	7 (11%)	2 (3%)	2 (17%)
	periodic limb movement disorder, N (%)	0 (0%)	1 (1%)	1 (8%)
	hypertension, N (%)	30 (46%)	39 (56%)	6 (50%)
	hyperlipidemia, N (%)	39 (60%)	28 (40%)	3 (25%)
	diabetes mellitus, N (%)	4 (6%)	6 (9%)	2 (17%)
	osteoarthritis, N (%)	34 (52%)	18 (26%)	8 (67%)
	rheumatoid arthritis, N (%)	1 (2%)	6 (9%)	0 (0%)
	coronary artery disease, N (%)	2 (3%)	6 (9%)	1 (8%)
	congestive heart disease, N (%)	2 (3%)	3 (4%)	1 (8%)
	hypothyroidism, N (%)	7 (6%)	5 (7%)	3 (25%)
	asthma/COPD, N (%)	9 (14%)	6 (9%)	3 (25%)
	cancer, N (%)	4 (6%)	5 (7%)	0, 2 n.d. (0%)
	antidepressant intake, N (%)	5, 1 n.d. (6%)	5 (7%)	0 (0%)
	current diabetes and/or metformin intake, N (%)	6 (9%)	6 (9%)	2 (17%)
	metformin intake, N (%)	3 (5%)	3 (4%)	2 (17%)

Characteristics of the cohort with stool samples analyzed by 16S rRNA gene amplicon sequencing

Study group		HC	PD	iRBD
	N	38	26	20
Demographics				
	Male/female (% male)	25/13 (66%)	19/7 (73%)	12/8 (60%)
	age, years [mean +/- standard deviation]	69.84 +/- 6.6	65.96 +/- 8.01	66.05 +/- 8.13
Anthropometrics				
	weight, kg [mean +/- standard deviation]	80.55 +/- 14.92	85.09 +/- 13.69	78.76 +/- 14.22
	height, cm [mean +/- standard deviation]	172.55 +/- 8.92	173.17 +/- 9.19	172.75 +/- 10.17
	BMI, kg/(m ² m) [mean +/- standard deviation]	26.9 +/- 3.68	28.47 +/- 4.05	26.3 +/- 3.46
Motor Symptoms				
	Hoehn and Yahr staging [mean +/- standard deviation]	0 +/- 0	2 +/- 0.58	0.05 +/- 0.22
	MDS-UPDRS II, sum [mean +/- standard deviation]	1.42 +/- 1.93	11.38 +/- 5.39	3.35 +/- 2.96
	MDS-UPDRS III, sum [mean +/- standard deviation]	1.5 +/- 2.83	27.46 +/- 11.81	3.95 +/- 3.2
	MDS-UPDRS IV, sum [mean +/- standard deviation]	0 +/- 0	0.69 +/- 1.26	0 +/- 0
	MDS-UPDRS, sum [mean +/- standard deviation]	8.97 +/- 7.33	49.81 +/- 20.11	19.55 +/- 8.94
Non-motor symptoms				
	MDS-UPDRS I, sum [mean +/- standard deviation]	6.05 +/- 4.05	10.27 +/- 6.35	12.25 +/- 5.87
	MDS-UPDRS anxiety (Question I.4) [mean +/- standard deviation]	0.26 +/- 0.6	0.5 +/- 0.76	1.1 +/- 0.97
	MDS-UPDRS pain (Question I.9) [mean +/- standard deviation]	0.68 +/- 0.77	1.08 +/- 1.2	0.95 +/- 0.69
	MDS-UPDRS constipation (Question I.11) [mean +/- standard deviation]	0.32 +/- 0.77	0.77 +/- 0.95	1 +/- 1.21
	Scopa-AUT, sum [mean +/- standard deviation]	7.58 +/- 5.58	13 +/- 6.41	12.3 +/- 5.58
	Scopa-AUT gastrointestinal part (Questions 1-7), sum [mean +/- standard deviation]	0.82 +/- 1.09	3.16 +/- 2.36	3.1 +/- 1.97
		often:2 (5%); sometimes:4 (11%); never:32 (84%)	often:1 (4%); regularly:1 (4%); never:16 (62%)	often:1 (5%); regularly:1 (5%); never:9 (45%); sometimes:9 (45%)
	Scopa-AUT constipation (Question 5)	4/34 (11%)	11/15 (42%)	8/12 (40%)
	NMS-Quest constipation (Question 5), yes/no (%)	0.08 +/- 0.36	0 +/- 0	0.7 +/- 1.45
	constipation by interview, N (%)	1 (3%)	4 (15%)	n.d.
	other GI dysfunction by interview, N (%)	6 (16%)	8 (33%)	n.d.
	Beck depression inventory (BDI), sum [mean +/- standard deviation]	2.95 +/- 3.02	6.76 +/- 7.01	6.47 +/- 5.51
	Geriatric Depression Scale (GDS), sum [mean +/- standard deviation]	1.11 +/- 1.54	2.53 +/- 2.57	2.55 +/- 2.4
	Epworth Sleepiness Scale (ESS), sum [mean +/- standard deviation]	5.56 +/- 3.21	8.27 +/- 3.69	9.5 +/- 4.36
	Mini-Mental-State-Examination (MMSE), total score [mean +/- standard deviation]	28.5 +/- 1.91	28.5 +/- 1.7	28.75 +/- 0.79
	Montreal Cognitive Assessment (MoCa), total score [mean +/- standard deviation]	25.76 +/- 3.03	25.46 +/- 3.54	23.75 +/- 3.27
	Montgomery-Åsberg Depression Rating Scale (MADRS), sum [mean +/- standard deviation]	1.69 +/- 4.6	3.19 +/- 4.31	5.15 +/- 6.29
	RBD by polysomnography, N	0	13; 2 n.d.	20
	Smell identification test (by 16 item Sniffin Sticks) [mean +/- standard deviation]	11.5 +/- 2.86	5.35 +/- 2.99	6.21 +/- 3.94
Intake of PD medication				
	Azilect, N (%)	0 (0%)	20 (77%)	0 (0%)
	any MAO-B inhibitors, N (%)	0 (0%)	21 (81%)	0 (0%)
	Levodopa, N (%)	0 (0%)	20, (77%)	0 (0%)
	L-Dopa agonists, N (%)	0 (0%)	22 (85%)	0 (0%)
	COMT inhibitors, N (%)	0 (0%)	1 (4%)	0 (0%)
	OTHER: macrogol intake, N (%)	1 (3%)	2 (8%)	0 (0%)
Medical history				
	depression, N (%)	4 (11%)	0 (0%)	6 (30%)
	anxiety, N (%)	0 (0%)	0 (0%)	3, 1 n.d. (16%)
	sleep apnoe, N (%)	6 (16%)	1 (4%)	3 (15%)
	periodic limb movement disorder, N (%)	0 (0%)	0 (0%)	1 (5%)
	hypertension, N (%)	18 (47%)	12 (46%)	10 (50%)
	hyperlipidemia, N (%)	23 (61%)	7 (27%)	7 (35%)
	diabetes mellitus, N (%)	3 (8%)	0 (0%)	3 (15%)
	osteoarthritis, N (%)	14 (37%)	3 (12%)	10 (50%)
	rheumatoid arthritis, N (%)	1 (3%)	2 (8%)	0 (0%)
	coronary artery disease, N (%)	1 (3%)	2 (8%)	2 (10%)
	congestive heart disease, N (%)	2 (5%)	2 (8%)	1 (5%)
	hypothyroidism, N (%)	4 (11%)	3 (12%)	3 (15%)
	asthma/COPD, N (%)	4 (11%)	0 (0%)	5 (25%)
	cancer, N (%)	1 (3%)	0 (0%)	0 (0%)
	antidepressant intake, N (%)	2, 1 n.d. (6%)	1 (4%)	0 (0%)
	current diabetes and/or metformin intake, N (%)	3 (8%)	1 (4%)	3 (15%)
	metformin intake, N (%)	1 (3%)	1 (4%)	3 (15%)

Characteristics of the cohort with stool samples analyzed by 18S rRNA gene amplicon sequencing

Study group	N	HC 32	PD 14	iRBD 15
Demographics				
Male/female (% male)		20/12 (63%)	10/4 (71%)	9/6 (50%)
age, years [mean +/- standard deviation]		69.31 +/- 5.9	65.43 +/- 6.57	65.87 +/- 7.86
Anthropometrics				
weight, kg [mean +/- standard deviation]		79.89 +/- 14.92	84.27 +/- 13.42	81.75 +/- 14.74
height, cm [mean +/- standard deviation]		173.12 +/- 8.43	173.61 +/- 10.66	173.73 +/- 11.1
BMI, kg/(m ²) [mean +/- standard deviation]		26.51 +/- 3.77	28 +/- 4.12	27.02 +/- 3.69
Motor Symptoms				
Hoehn and Yahr staging [mean +/- standard deviation]		0 +/- 0	2.04 +/- 0.66	0.07 +/- 0.26
MDS-UPDRS II, sum [mean +/- standard deviation]		1.16 +/- 1.55	10.29 +/- 4.87	3.27 +/- 2.55
MDS-UPDRS III, sum [mean +/- standard deviation]		1.34 +/- 2.39	26.93 +/- 12.72	3.67 +/- 3.31
MDS-UPDRS IV, sum [mean +/- standard deviation]		0 +/- 0	0.93 +/- 1.49	0 +/- 0
MDS-UPDRS, sum [mean +/- standard deviation]		8.59 +/- 6.67	48.57 +/- 21.06	19.6 +/- 8.85
Non-motor symptoms				
MDS-UPDRS I, sum [mean +/- standard deviation]		6.09 +/- 4.21	10.43 +/- 7.23	12.67 +/- 5.89
MDS-UPDRS anxiety (Question I.4) [mean +/- standard deviation]		0.28 +/- 0.63	0.64 +/- 0.84	1.2 +/- 0.86
MDS-UPDRS pain (Question I.9) [mean +/- standard deviation]		0.75 +/- 0.8	0.93 +/- 1.27	1.07 +/- 0.59
MDS-UPDRS constipation (Question I.11) [mean +/- standard deviation]		0.38 +/- 0.83	0.86 +/- 1.03	1 +/- 1.2
Scopa-AUT, sum [mean +/- standard deviation]		7.72 +/- 5.85	13.18 +/- 6.29	12.27 +/- 6.31
Scopa-AUT gastrointestinal part (Questions 1-7), sum [mean +/- standard deviation]		0.84 +/- 1.14	3.08 +/- 2.5	3.33 +/- 2.16
			regularly:1 (8%); often:2 (6%); sometimes:3 (9%); never:27 (84%)	often:1 (7%); regularly:1 (7%); sometimes:7 (47%); never:6 (40%);
Scopa-AUT constipation (Question 5)		never:27 (84%)	1 n.d.	never:6 (40%);
NMS-Quest constipation (Question 5), yes/no (%)		4/28 (13%)	6/8 (43%)	7/8 (47%)
Non-motor symptom assessment scale (NMSS) constipation (Question 21, strength*frequency) [mean +/- standard deviation]		0.09 +/- 0.39	0 +/- 0	0.67 +/- 1.4
constipation by interview, N (%)		1 (3%)	2 (14%)	n.d.
other GI dysfunction by interview, N (%)		6 (19%)	4 (29%)	n.d.
Beck depression inventory (BDI), sum [mean +/- standard deviation]		3.1 +/- 3.16	7.67 +/- 7.89	6.37 +/- 6.26
Geriatric Depression Scale (GDS), sum [mean +/- standard deviation]		1.1 +/- 1.51	3.26 +/- 3.13	2.94 +/- 2.61
Epworth Sleepiness Scale (ESS), sum [mean +/- standard deviation]		5.62 +/- 3.17	8.36 +/- 3.1	9.5 +/- 4.36
Mini-Mental-State-Examination (MMSE), total score [mean +/- standard deviation]		28.91 +/- 1.38	28.57 +/- 2.03	28.67 +/- 0.82
Montreal Cognitive Assessment (MoCa), total score [mean +/- standard deviation]		26.19 +/- 2.26	25 +/- 3.74	23.33 +/- 3.39
Montgomery-Åsberg Depression Rating Scale (MADRS), sum [mean +/- standard deviation]		1.87 +/- 4.92	3.5 +/- 4.82	6.53 +/- 6.67
RBD by polysomnography, N		0	9; 1 n.d.	15
Smell identification test (by 16 item Sniffin Sticks) [mean +/- standard deviation]		11.47 +/- 2.66	5.43 +/- 2.98	5.86 +/- 3.84
Intake of PD medication				
Azilect, N (%)		0 (0%)	9 (64%)	0 (0%)
any MAO-B inhibitors, N (%)		0 (0%)	10 (71%)	0 (0%)
Levodopa, N (%)		0 (0%)	12 (86%)	0 (0%)
L-Dopa agonists, N (%)		0 (0%)	12 (86%)	0 (0%)
COMT inhibitors, N (%)		0 (0%)	1 (7%)	0 (0%)
OTHER: macrogol intake, N (%)		1 (3%)	2 (14%)	0 (0%)
Medical history				
depression, N (%)		4 (13%)	0 (0%)	4 (27%)
anxiety, N (%)		0 (0%)	0 (0%)	2, 1 n.d. (14%)
sleep apnoe, N (%)		4 (13%)	0 (0%)	3 (20%)
periodic limb movement disorder, N (%)		0 (0%)	0 (0%)	1 (7%)
hypertension, N (%)		14 (44%)	5 (36%)	6 (40%)
hyperlipidemia, N (%)		20 (63%)	3 (21%)	4 (27%)
diabetes mellitus, N (%)		2 (6%)	0 (0%)	1 (7%)
osteoarthritis, N (%)		14 (44%)	2 (14%)	7 (47%)
rheumatoid arthritis, N (%)		1 (3%)	2 (14%)	0 (0%)
coronary artery disease, N (%)		1 (3%)	0 (0%)	1 (7%)
congestive heart disease, N (%)		2 (6%)	1 (7%)	1 (7%)
hypothyroidism, N (%)		3 (9%)	2 (14%)	3 (20%)
asthma/COPD, N (%)		3 (9%)	0 (0%)	4 (27%)
cancer, N (%)		0 (0%)	0 (0%)	0 (0%)
antidepressant intake, N (%)		1, 1 n.d. (6%)	1 (7%)	0 (0%)
current diabetes and/or metformin intake, N (%)		2 (6%)	1 (7%)	1 (7%)
metformin intake, N (%)		1 (3%)	1 (7%)	1 (7%)

comparison PD versus HC

KEGG orthologous group	HC mean % abundan	greater median in	estimate of location parameter	P-Value (Wilcoxon rank sum test)	adjusted P-value	KEGG description
K13038	0.069%	HC	-0.0049%	0.004	1.0	dfp; fused 4'-phosphopantothenoylcysteine decarboxylase/phosphopantothenoylcysteine synthetase, FMN-binding (EC:4.1.1.36 6.3.2.5); K13038 phosphopantothenoylcysteine decarboxylase / phosphopantothenate--cysteine ligase [EC:4.1.1.36 6.3.2.5] (A)
K01749	0.022%	PD	0.0032%	0.009	1.0	HMBS, PBG-D, PBGD, PORC, UPS; hydroxymethylbilane synthase (EC:2.5.1.61); K01749 hydroxymethylbilane synthase [EC:2.5.1.61] (A)
K01845	0.032%	PD	0.0019%	0.006	1.0	GSA2; glutamate-1-semialdehyde 2,1-aminomutase 2; K01845 glutamate-1-semialdehyde 2,1-aminomutase [EC:5.4.3.8] (A)
K00925	0.078%	HC	0.0005%	0.007	1.0	similar to acetate kinase; K00925 acetate kinase [EC:2.7.2.1] (A)
K02492	0.025%	PD	0.0042%	0.004	1.0	HEMA2; glutamyl-tRNA reductase 2; K02492 glutamyl-tRNA reductase [EC:1.2.1.70] (A)
K09812	0.073%	HC	-0.0057%	0.005	1.0	ftsE; predicted transporter subunit: ATP-binding component of ABC superfamily; K09812 cell division transport system ATP-binding protein (A)
K06998	0.013%	PD	0.0027%	0.007	1.0	PBLD, MAWBP, MAWDBP; phenazine biosynthesis-like protein domain containing; K06998 (A)
K02049	0.027%	PD	0.0034%	0.004	1.0	putative ABC transporter; K02049 NitT/TauT family transport system ATP-binding protein (A)
K01607	0.028%	PD	0.0030%	0.005	1.0	AO090038000029; 4-carboxymuconolactone decarboxylase; K01607 4-carboxymuconolactone decarboxylase [EC:4.1.1.44] (A)
K00537	0.011%	PD	0.0027%	0.003	1.0	arsenate reductase-like; K00537 arsenate reductase [EC:1.20.4.1] (A)
K03783	0.065%	HC	0.0004%	0.009	1.0	PNP, NP, PRO1837, PUNP; purine nucleoside phosphorylase (EC:2.4.2.1); K03783 purine-nucleoside phosphorylase [EC:2.4.2.1] (A)
K02652	0.019%	PD	0.0033%	0.004	1.0	pilus biogenesis protein; K02652 type IV pilus assembly protein PilB (A)
K02669	0.035%	PD	0.0030%	0.005	1.0	yggR; predicted pilus retraction ATPase; K02669 twitching motility protein PilT (A)
K00100	0.016%	PD	0.0029%	0.001	1.0	Akr1c6, 3alpha-HSD, Ak1c1, Hsd17b5; aldo-keto reductase family 1, member C6; K00100 [EC:1.1.1.-] (A)
K01966	0.003%	PD	0.0027%	0.005	1.0	PCCB; propionyl CoA carboxylase, beta polypeptide (EC:6.4.1.3); K01966 propionyl-CoA carboxylase beta chain [EC:6.4.1.3] (A)
K01447	0.007%	PD	0.0060%	0.007	1.0	N-acetylmuramoyl-L-alanine amidase; K01447 N-acetylmuramoyl-L-alanine amidase [EC:3.5.1.28] (A)
K00955	0.008%	PD	0.0018%	0.001	1.0	nodQ; bifunctional sulfate adenyltransferase/adenyl-sulfate kinase (EC:2.7.1.25 2.7.7.4); K00955 bifunctional enzyme CysN/CysC [EC:2.7.7.4 2.7.1.25] (A)
K13542	0.020%	PD	0.0035%	0.006	1.0	hemD; uroporphyrinogen III C2,C7-methyltransferase and uroporphyrinogen III synthase; K13542 uroporphyrinogen III methyltransferase / synthase [EC:2.1.1.107 4.2.1.75] (A)
K07192	0.018%	PD	0.0008%	0.009	1.0	FLOT1; flotillin 1; K07192 flotillin (A)
K09940	0.002%	PD	0.0028%	0.009	1.0	hypothetical protein; K09940 hypothetical protein (A)
K03818	0.002%	PD	0.0026%	0.007	1.0	wcaF; predicted acyl transferase; K03818 putative colanic acid biosynthesis acetyltransferase WcaF [EC:2.3.1.-] (A)
K16870	0.000%	PD	0.0000%	0.007	1.0	N-acetylglucosaminyl-diphospho-decaprenol L-rhamnosyltransferase [EC:2.4.1.289]

comparison iRBD versus HC

KEGG orthologous group	HC mean % abundan	greater median in	estimate of location parameter	P-Value (Wilcoxon rank sum test)	adjusted P-value	KEGG description
K02863	0.080%	HC	-0.0022%	0.009	0.4	PRPL1; Plastid ribosomal protein L1 large ribosomal subunit; K02863 large subunit ribosomal protein L1 (A)
K02906	0.080%	HC	-0.0022%	0.009	0.4	50S ribosomal protein L3-1; K02906 large subunit ribosomal protein L3 (A)
K02933	0.072%	HC	-0.0014%	0.007	0.4	emb2394; 50S ribosomal protein L6; K02933 large subunit ribosomal protein L6 (A)
K02950	0.080%	HC	-0.0022%	0.008	0.4	rps12; ribosomal protein S12; K02950 small subunit ribosomal protein S12 (A)
K02967	0.079%	HC	-0.0024%	0.010	0.4	rps2; 30S ribosomal protein S2; K02967 small subunit ribosomal protein S2 (A)
K02996	0.061%	HC	-0.0056%	0.010	0.4	RPS9; 30S ribosomal protein S9; K02996 small subunit ribosomal protein S9 (A)
K01533	0.080%	HC	-0.0008%	0.008	0.4	ATP7A, DSMAX, MK, MNK, SMAX3; ATPase, Cu ⁺⁺ transporting, alpha polypeptide (EC:3.6.3.4); K01533 Cu ²⁺ -exporting ATPase [EC:3.6.3.4] (A)
K00600	0.076%	HC	-0.0036%	0.009	0.4	SHMT1, CSHMT, SHMT; serine hydroxymethyltransferase 1 (soluble) (EC:2.1.2.1); K00600 glycine hydroxymethyltransferase [EC:2.1.2.1] (A)
K00820	0.082%	HC	-0.0031%	0.005	0.4	GFPT1, GFA, GFAT, GFAT_1, GFAT1, GFAT1m, GFPT, GFPT1L, MSLG; glutamine--fructose-6-phosphate transaminase 1 (EC:2.6.1.16); K00820 glucosamine--fructose-6-phosphate aminotransferase (isomerizing) [EC:2.6.1.16] (A)
K04077	0.082%	HC	-0.0027%	0.008	0.4	HSPD1, CPN60, GROEL, HLD4, HSP-60, HSP60, HSP65, HuCHA60, SPG13; heat shock 60kDa protein 1 (chaperonin); K04077 chaperonin GroEL (A)
K03168	0.073%	HC	-0.0005%	0.007	0.4	DNA topoisomerase-like protein (EC:5.99.1.2); K03168 DNA topoisomerase I [EC:5.99.1.2] (A)
K00609	0.080%	HC	-0.0026%	0.007	0.4	PYRB; aspartate carbamoyltransferase; K00609 aspartate carbamoyltransferase catalytic subunit [EC:2.1.3.2] (A)
K04078	0.082%	HC	-0.0026%	0.003	0.3	HSPE1, CPN10, EPF, GROES, HSP10; heat shock 10kDa protein 1 (chaperonin 10); K04078 chaperonin GroES (A)
K00602	0.084%	HC	-0.0037%	0.003	0.3	ATIC, AICAR, AICARFT, IMPCHASE, PURH; 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (EC:2.1.2.3 3.5.4.10); K00602 phosphoribosylaminoimidazolecarboxamide formyltransferase / IMP cyclohydrolase [EC:2.1.2.3 3.5.4.10] (A)
K02887	0.080%	HC	-0.0023%	0.010	0.4	rpl20; 50S ribosomal protein L20; K02887 large subunit ribosomal protein L20 (A)
K02355	0.127%	HC	-0.0047%	0.009	0.4	GFM2, EF-G2mt, EFG2, MRRF2, MST027, RRF2, RRF2mt, hEFG2, mEF-G_2; G elongation factor, mitochondrial 2; K02355 elongation factor G (A)
K02358	0.084%	HC	-0.0033%	0.004	0.4	TUFM, COXPD4, EF-TuMT, EFTU, P43; Tu translation elongation factor, mitochondrial; K02358 elongation factor Tu (A)
K02926	0.079%	HC	-0.0023%	0.010	0.4	RPL4; 50S ribosomal protein L4; K02926 large subunit ribosomal protein L4 (A)
K03086	0.131%	HC	-0.0141%	0.001	0.3	SIGA; sigma factor A; K03086 RNA polymerase primary sigma factor (A)
K03977	0.079%	HC	-0.0023%	0.009	0.4	GTPase Der-like; K03977 GTP-binding protein (A)
K01924	0.081%	HC	-0.0021%	0.004	0.3	murC; UDP-N-acetylmuramate:L-alanine ligase (EC:6.3.2.8); K01924 UDP-N-acetylmuramate--alanine ligase [EC:6.3.2.8] (A)
K03723	0.081%	HC	-0.0023%	0.004	0.3	mfd; transcription-repair coupling factor; K03723 transcription-repair coupling factor (superfamily II helicase) [EC:3.6.4.-] (A)
K06997	0.080%	HC	-0.0029%	0.007	0.4	PROSC; proline synthetase co-transcribed homolog (bacterial); K06997 (A)
K02907	0.078%	HC	-0.0010%	0.007	0.4	large subunit ribosomal protein L30; K02907 large subunit ribosomal protein L30 (A)
K02860	0.081%	HC	-0.0024%	0.004	0.3	RimM-like protein; K02860 16S rRNA processing protein RimM (A)
K00817	0.082%	HC	-0.0035%	0.002	0.3	HISN6B; Histidinol-phosphate aminotransferase; K00817 histidinol-phosphate aminotransferase [EC:2.6.1.9] (A)
K01262	0.089%	HC	-0.0023%	0.001	0.3	XPNPEP3, APP3, NPHPL1; X-prolyl aminopeptidase (aminopeptidase P) 3, putative (EC:3.4.11.9); K01262 Xaa-Pro aminopeptidase [EC:3.4.11.9] (A)
K06287	0.082%	HC	-0.0027%	0.004	0.4	1810009N02Rik; RIKEN cDNA 1810009N02 gene; K06287 septum formation protein (A)
K02013	0.144%	RBD	0.0055%	0.003	0.3	fhuC; iron-hydroxamate transporter subunit; K02013 iron complex transport system ATP-binding protein [EC:3.6.3.34] (A)
K06966	0.049%	HC	-0.0082%	0.004	0.4	LOG1; cytokinin riboside 5'-monophosphate phosphoribohydrolase LOG1; K06966 (A)
K02015	0.189%	RBD	0.0057%	0.003	0.3	fhuB; fused iron-hydroxamate transporter subunits of ABC superfamily: membrane components; K02015 iron complex transport system permease protein (A)
K00645	0.082%	HC	-0.0029%	0.006	0.4	MCAT, FASN2C, MCT, MT, NET62, fabD; malonyl CoA:ACP acyltransferase (mitochondrial) (EC:2.3.1.39); K00645 [acyl-carrier-protein] S-malonyltransferase [EC:2.3.1.39] (A)
K04485	0.075%	HC	-0.0036%	0.003	0.3	DNA repair protein RadA homolog; K04485 DNA repair protein RadA/Sms (A)
K01776	0.066%	HC	-0.0046%	0.003	0.3	murl; glutamate racemase (EC:5.1.1.3); K01776 glutamate racemase [EC:5.1.1.3] (A)
K01652	0.115%	RBD	0.0053%	0.006	0.4	similar to 2-hydroxyacyl-CoA lyase 1; K01652 acetolactate synthase I/II/III large subunit [EC:2.2.1.6] (A)
K00648	0.083%	HC	-0.0052%	0.004	0.3	KAS_III; 3-oxoacyl-[acyl-carrier-protein] synthase III; K00648 3-oxoacyl-[acyl-carrier-protein] synthase III [EC:2.3.1.180] (A)
K01778	0.090%	RBD	0.0072%	0.009	0.4	diaminopimelate epimerase; K01778 diaminopimelate epimerase [EC:5.1.1.7] (A)
K00640	0.110%	HC	-0.0051%	0.003	0.3	SERAT2;1; serine O-acetyltransferase; K00640 serine O-acetyltransferase [EC:2.3.1.30] (A)
K01662	0.088%	HC	-0.0054%	0.001	0.3	DXPS1; 1-deoxy-D-xylulose 5-phosphate synthase 1; K01662 1-deoxy-D-xylulose-5-phosphate synthase [EC:2.2.1.7] (A)

K00759	0.058%	HC	-0.0068%	0.003	0.3	APRT, AMP; adenine phosphoribosyltransferase (EC:2.4.2.7); K00759 adenine phosphoribosyltransferase [EC:2.4.2.7] (A)
K01897	0.108%	HC	-0.0108%	0.008	0.4	ACSL1, ACS1, FAcl1, FAcl2, LACS, LACS1, LACS2; acyl-CoA synthetase long-chain family member 1 (EC:6.2.1.3); K01897 long-chain acyl-CoA synthetase [EC:6.2.1.3] (A)
K00616	0.050%	RBD	0.0038%	0.006	0.4	TALDO1, TAL, TAL-H, TALDOR, TALH; transaldolase 1 (EC:2.2.1.2); K00616 transaldolase [EC:2.2.1.2] (A)
K00950	0.023%	HC	-0.0050%	0.010	0.4	DHPS, PPPK; dihydropteroate synthetase (EC:2.5.1.15); K00796 dihydropteroate synthase [EC:2.5.1.15] K00950 2-amino-4-hydroxy-6-hydroxymethylidihydropteridine diphosphokinase [EC:2.7.6.3] (A)
K07560	0.071%	HC	-0.0037%	0.005	0.4	DTD1, C20orf88, DUEB, HARS2, bA379J5.3, bA555E18.1, pqn-68; D-tyrosyl-tRNA deacylase 1 homolog (<i>S. cerevisiae</i>) (EC:6.1.1.21); K07560 D-tyrosyl-tRNA(Tyr) deacylase [EC:3.1.-.-] (A)
K07567	0.075%	HC	-0.0015%	0.009	0.4	endoribonuclease L-PSP, putative; K07567 TdcF protein (A)
K01752	0.122%	RBD	0.0076%	0.007	0.4	SDS, SDH; serine dehydratase (EC:4.3.1.17 4.3.1.19); K01752 L-serine dehydratase [EC:4.3.1.17] (A)
K00831	0.078%	HC	-0.0021%	0.006	0.4	PSAT1, EPIP, PSA, PSAT; phosphoserine aminotransferase 1 (EC:2.6.1.52); K00831 phosphoserine aminotransferase [EC:2.6.1.52] (A)
K03786	0.047%	HC	-0.0084%	0.009	0.4	DEHA2F23584p; K03786 3-dehydroquinone dehydratase II [EC:4.2.1.10] (A)
K01953	0.105%	RBD	0.0049%	0.003	0.3	ASNS, TS11; asparagine synthetase (glutamine-hydrolyzing) (EC:6.3.5.4); K01953 asparagine synthase (glutamine-hydrolyzing) [EC:6.3.5.4] (A)
K02687	0.077%	HC	-0.0030%	0.004	0.4	prmA; methyltransferase for 50S ribosomal subunit protein L11 (EC:2.1.1.-); K02687 ribosomal protein L11 methyltransferase [EC:2.1.1.-] (A)
K03978	0.080%	HC	-0.0025%	0.004	0.3	GTP-binding protein At2g22870-like; K03978 GTP-binding protein (A)
K03570	0.078%	HC	-0.0024%	0.001	0.3	mreC; cell wall structural complex MreBCD transmembrane component MreC; K03570 rod shape-determining protein MreC (A)
K02970	0.079%	HC	-0.0025%	0.009	0.4	rpsU; 30S ribosomal subunit protein S21; K02970 small subunit ribosomal protein S21 (A)
K01719	0.013%	HC	-0.0052%	0.006	0.4	UROS, UROIIS; uroporphyrinogen III synthase (EC:4.2.1.75); K01719 uroporphyrinogen-III synthase [EC:4.2.1.75] (A)
K02837	0.064%	HC	-0.0055%	0.003	0.3	prfC; peptide chain release factor RF-3; K02837 peptide chain release factor 3 (A)
K07636	0.077%	HC	-0.0005%	0.009	0.4	phoR; sensory histidine kinase in two-component regulatory system with PhoB (EC:2.7.3.-); K07636 two-component system, OmpR family, phosphate regulon sensor histidine kinase PhoR [EC:2.7.13.3] (A)
K06950	0.129%	HC	-0.0104%	0.006	0.4	Metal-dependent phosphohydrolase; K06950 uncharacterized protein (A)
K09760	0.042%	HC	-0.0060%	0.008	0.4	rnuC; predicted recombination limiting protein; K09760 DNA recombination protein RnuC (A)
K01187	0.099%	RBD	0.0098%	0.008	0.4	sucrase-isomaltase, intestinal-like; K01187 alpha-glucosidase [EC:3.2.1.20] (A)
K03699	0.047%	RBD	0.0067%	0.004	0.3	tlyC; hemolysin; K03699 putative hemolysin (A)
K05366	0.079%	HC	-0.0082%	0.000	0.3	mrcA; fused penicillin-binding protein 1a: murein transglycosylase/murein transpeptidase (EC:2.4.2.- 3.4.-.-); K05366 penicillin-binding protein 1A [EC:2.4.1.- 3.4.-.-] (A)
K01433	0.006%	HC	-0.0011%	0.003	0.3	Formyl transferase; K01433 formyltetrahydrofolate deformylase [EC:3.5.1.10] (A)
K07053	0.105%	RBD	0.0053%	0.003	0.3	Polymerase/histidinol phosphatase-like protein; K07053 (A)
K03547	0.045%	RBD	0.0081%	0.006	0.4	sbcD; exonuclease, dsDNA, ATP-dependent; K03547 exonuclease SbcD (A)
K03294	0.025%	RBD	0.0036%	0.005	0.4	uncharacterized LOC100776671; K03294 basic amino acid/polyamine antiporter, APA family (A)
K03581	0.045%	RBD	0.0040%	0.008	0.4	recD; exonuclease V (RecBCD complex), alpha chain (EC:3.1.11.5); K03581 exodeoxyribonuclease V alpha subunit [EC:3.1.11.5] (A)
K06890	0.034%	HC	-0.0084%	0.004	0.4	GRINA, HNRGW, LFG1, NMDARA1, TMBIM3; glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding); K06890 (A)
K01259	0.004%	HC	-0.0013%	0.002	0.3	PIP; proline iminopeptidase; K01259 proline iminopeptidase [EC:3.4.11.5] (A)
K09125	0.011%	HC	-0.0053%	0.005	0.4	yhhQ; inner membrane protein, DUF165 family; K09125 hypothetical protein (A)
K07054	0.004%	HC	-0.0027%	0.000	0.3	ypfJ; conserved protein; K07054 (A)
K05794	0.003%	HC	-0.0006%	0.000	0.3	terC; phage inhibition, colicin resistance and tellurite resistance protein; K05794 tellurite resistance protein TerC (A)
K03316	0.004%	HC	-0.0006%	0.004	0.4	CPA1 family transporter: sodium ion/proton; K03316 monovalent cation:H+ antiporter, CPA1 family (A)
K01151	0.047%	RBD	0.0043%	0.001	0.3	DNA LYASE/ENDONUCLEASE 4; K01151 deoxyribonuclease IV [EC:3.1.21.2] (A)
K00782	0.009%	HC	-0.0036%	0.006	0.4	ykgG; predicted transporter; K00782 hypothetical protein (A)
K07727	0.042%	RBD	0.0034%	0.007	0.4	XRE family transcriptional regulator; K07727 putative transcriptional regulator (A)
K05521	0.016%	HC	-0.0071%	0.003	0.3	yegU; predicted hydrolase; K05521 ADP-ribosylglycohydrolase [EC:3.2.-.-] (A)
K03549	0.005%	HC	-0.0007%	0.005	0.4	KT2; potassium transporter 2; K03549 KUP system potassium uptake protein (A)
K08281	0.005%	HC	-0.0040%	0.000	0.3	pncA; nicotinamidase/pyrazinamidase (EC:3.5.1.19 3.5.1.-); K08281 nicotinamidase/pyrazinamidase [EC:3.5.1.19 3.5.1.-] (A)
K03929	0.012%	HC	-0.0009%	0.008	0.4	putative esterase; K03929 para-nitrobenzyl esterase [EC:3.1.1.-] (A)
K01654	0.022%	RBD	0.0029%	0.007	0.4	neuB; sialic acid synthase NeuB (EC:1.2.4.1); K01654 N-acetylneuraminase synthase [EC:2.5.1.56] (A)
K06177	0.010%	HC	-0.0053%	0.003	0.3	rluA; pseudouridine synthase for 23S rRNA (position 746) and tRNAphe(position 32) (EC:4.2.1.70); K06177 tRNA pseudouridine32 synthase / 23S rRNA pseudouridine746 synthase [EC:5.4.99.28 5.4.99.29] (A)
K07259	0.012%	HC	-0.0065%	0.001	0.3	dacB; D-alanyl-D-alanine carboxypeptidase (EC:3.4.16.4); K07259 D-alanyl-D-alanine carboxypeptidase / D-alanyl-D-alanine-endopeptidase (penicillin-binding protein 4) [EC:3.4.16.4 3.4.21.-] (A)
K08963	0.028%	RBD	0.0050%	0.008	0.4	MRI1, MTNA, Ypr118w; methylthioribose-1-phosphate isomerase homolog (<i>S. cerevisiae</i>) (EC:5.3.1.23); K08963 methylthioribose-1-phosphate isomerase [EC:5.3.1.23] (A)
K04651	0.036%	RBD	0.0037%	0.004	0.4	hypA; protein involved in nickel insertion into hydrogenases 3; K04651 hydrogenase nickel incorporation protein HypA/HybF (A)
K04652	0.034%	RBD	0.0038%	0.003	0.3	hypB; GTP hydrolase involved in nickel liganding into hydrogenases; K04652 hydrogenase nickel incorporation protein HypB (A)
K01417	0.009%	RBD	0.0023%	0.007	0.4	ATP-dependent Zn protease FtsH2; K01417 [EC:3.4.24.-] (A)

						HDDC2, C6orf74, NS5ATP2, dJ16705.2; HD domain containing 2; K07023 putative hydrolases of HD superfamily (A)
K07023	0.036%	RBD	0.0039%	0.010	0.4	
K07185	0.013%	RBD	0.0011%	0.003	0.3	TspO/MBR family protein; K07185 tryptophan-rich sensory protein (A)
						cbpA; curved DNA-binding protein, DnaJ homologue that functions as a co-chaperone of DnaK; K05516 curved DNA-binding protein (A)
K05516	0.011%	HC	-0.0059%	0.004	0.4	
						CMAS, CSS; cytidine monophosphate N-acetylneuraminic acid synthetase (EC:2.7.7.43); K00983 N-acylneuraminic acid cytidyltransferase [EC:2.7.7.43] (A)
K00983	0.023%	RBD	0.0033%	0.007	0.4	
K10536	0.023%	RBD	0.0047%	0.008	0.4	EMB1873; agmatine deiminase; K10536 agmatine deiminase [EC:3.5.3.12] (A)
						DNA mismatch repair protein MutS2; K07456 DNA mismatch repair protein MutS2 (A)
K07456	0.075%	HC	-0.0017%	0.009	0.4	
						putative toxin-plasmid maintenance system killer protein; K07334 proteic killer suppression protein (A)
K07334	0.006%	HC	-0.0017%	0.001	0.3	
						ATOX1, ATX1, HAH1; ATX1 antioxidant protein 1 homolog (yeast) (EC:6.2.1.2); K07213 copper chaperone (A)
K07213	0.012%	HC	-0.0047%	0.008	0.4	
						PPOX, PPO, V290M, VP; protoporphyrinogen oxidase (EC:1.3.3.4); K00231 oxygen-dependent protoporphyrinogen oxidase [EC:1.3.3.4] (A)
K00231	0.005%	HC	-0.0033%	0.002	0.3	
						mgsA; methylglyoxal synthase (EC:4.2.3.3); K01734 methylglyoxal synthase [EC:4.2.3.3] (A)
K01734	0.099%	RBD	0.0102%	0.004	0.4	
						cbiM; cobalamin biosynthesis protein CbiM; K02007 cobalt/nickel transport system permease protein (A)
K02007	0.029%	RBD	0.0027%	0.001	0.3	
						ABC transporter ATP-binding protein; K02006 cobalt/nickel transport system ATP-binding protein (A)
K02006	0.029%	RBD	0.0029%	0.001	0.3	
						ISYNA1, INO1, INOS, IPS, IPS_1, IPS-1; inositol-3-phosphate synthase 1 (EC:5.5.1.4); K01858 myo-inositol-1-phosphate synthase [EC:5.5.1.4] (A)
K01858	0.006%	HC	-0.0007%	0.002	0.3	
K01442	0.059%	RBD	0.0099%	0.006	0.4	choloylglycine hydrolase; K01442 choloylglycine hydrolase [EC:3.5.1.24] (A)
						ahpF; alkyl hydroperoxide reductase, F52a subunit, FAD/NAD(P)-binding (EC:1.11.1.15); K03387 alkyl hydroperoxide reductase subunit F [EC:1.6.4.-] (A)
K03387	0.012%	HC	-0.0033%	0.008	0.4	
						ompA; outer membrane protein A (3a;II*;G;d); K03286 OmpA-OmpF porin, OOP family (A)
K03286	0.005%	HC	-0.0009%	0.010	0.4	
						rfaF; ADP-heptose:LPS heptosyltransferase II (EC:2.-.-.-); K02843 heptosyltransferase II [EC:2.4.-.-] (A)
K02843	0.005%	HC	-0.0023%	0.006	0.4	
						asnC; DNA-binding transcriptional dual regulator; K03718 Lrp/AsnC family transcriptional regulator, regulator for asnA, asnC and gidA (A)
K03718	0.019%	HC	-0.0016%	0.007	0.4	
K08987	0.002%	HC	0.0040%	0.002	0.3	integral membrane protein; K08987 putative membrane protein (A)
K01552	0.013%	RBD	0.0022%	0.007	0.4	PfATPase7; P-type ATPase, putative (EC:3.6.3.-); K01552 [EC:3.6.3.-] (A)
						ihfA; integration host factor (IHF), DNA-binding protein, alpha subunit; K04764 integration host factor subunit alpha (A)
K04764	0.004%	HC	-0.0033%	0.001	0.3	
K06973	0.049%	RBD	0.0091%	0.002	0.3	peptidase membrane zinc metallopeptidase; K06973 (A)
K08974	0.036%	RBD	0.0077%	0.006	0.4	membrane protein; K08974 putative membrane protein (A)
						glycine cleavage system protein P; K00282 glycine dehydrogenase subunit 1 [EC:1.4.4.2] (A)
K00282	0.011%	HC	-0.0013%	0.006	0.4	
						glycine cleavage system protein P; K00283 glycine dehydrogenase subunit 2 [EC:1.4.4.2] (A)
K00283	0.011%	HC	-0.0013%	0.006	0.4	
						fes; enterobactin/ferric enterobactin esterase; K07214 enterochelin esterase and related enzymes (A)
K07214	0.007%	HC	-0.0001%	0.006	0.4	
						entC; isochorismate synthase 1 (EC:5.4.4.2); K02361 isochorismate synthase [EC:5.4.4.2] (A)
K02361	0.009%	HC	-0.0005%	0.003	0.3	
						chlorohydrolase family protein; K12960 5-methylthioadenosine/S-adenosylhomocysteine deaminase [EC:3.5.4.31 3.5.4.28] (A)
K12960	0.029%	RBD	0.0038%	0.009	0.4	
K07273	0.012%	HC	-0.0003%	0.001	0.3	yegX; predicted hydrolase; K07273 lysozyme (A)
						macrolide-efflux protein; K08217 MFS transporter, DHA3 family, macrolide efflux protein (A)
K08217	0.037%	RBD	0.0035%	0.004	0.3	
						djIA; DnaJ-like protein, membrane anchored; K05801 DnaJ like chaperone protein (A)
K05801	0.010%	HC	-0.0023%	0.003	0.3	
K07284	0.011%	RBD	0.0020%	0.004	0.4	LPXTG-site transpeptidase; K07284 sortase A [EC:3.4.22.70] (A)
K07192	0.018%	RBD	0.0020%	0.009	0.4	FLOT1; flotillin 1; K07192 flotillin (A)
K07454	0.003%	HC	-0.0028%	0.001	0.3	HNH nuclease; K07454 putative restriction endonuclease (A)
						DPP4, ADABP, ADCP2, CD26, DPPIV, TP103; dipeptidyl-peptidase 4 (EC:3.4.14.5); K01278 dipeptidyl-peptidase 4 [EC:3.4.14.5] (A)
K01278	0.019%	HC	-0.0066%	0.004	0.3	
K09702	0.022%	RBD	0.0050%	0.007	0.4	REE1; Ree1p; K09702 hypothetical protein (A)
K01185	0.003%	HC	-0.0063%	0.001	0.3	LYZL2; lysozyme-like 2 (EC:3.2.1.17); K01185 lysozyme [EC:3.2.1.17] (A)
						FBP11-1; peptidyl-prolyl cis-trans isomerase, FKBP-type; K03773 FKBP-type peptidyl-prolyl cis-trans isomerase FkIB [EC:5.2.1.8] (A)
K03773	0.012%	HC	-0.0022%	0.008	0.4	
						GntR family transcriptional regulator; K07979 GntR family transcriptional regulator (A)
K07979	0.032%	RBD	0.0042%	0.009	0.4	
						NosD, nitrous oxidase accessory protein; K07218 nitrous oxidase accessory protein (A)
K07218	0.001%	HC	0.0016%	0.000	0.3	
						xanthine phosphoribosyltransferase (EC:2.4.2.22); K03816 xanthine phosphoribosyltransferase [EC:2.4.2.22] (A)
K03816	0.060%	HC	-0.0028%	0.006	0.4	
K06990	0.002%	HC	0.0020%	0.003	0.3	MEMO1, C2orf4, MEMO, NS5ATP7; mediator of cell motility 1; K06990 (A)
						nitrous-oxide reductase (EC:1.7.99.6); K00376 nitrous-oxide reductase [EC:1.7.2.4] (A)
K00376	0.001%	HC	0.0016%	0.000	0.3	
K13626	0.022%	RBD	0.0026%	0.010	0.4	flagellar assembly protein FliW; K13626 flagellar assembly factor FliW (A)
						peptidoglycan glycosyltransferase (EC:2.4.1.129); K05364 peptidoglycan glycosyltransferase [EC:2.4.1.129] (A)
K05364	0.012%	RBD	0.0005%	0.005	0.4	
K16922	0.002%	HC	-0.0047%	0.000	0.3	putative peptide zinc metalloprotease protein
K08984	0.002%	HC	0.0020%	0.000	0.3	yjdB; conserved inner membrane protein; K08984 putative membrane protein (A)
						cytR; DNA-binding transcriptional dual regulator; K05499 LacI family transcriptional regulator, repressor for deo operon, udp, cdd, tsx, nupC, and nupG (A)
K05499	0.001%	HC	-0.0044%	0.001	0.3	
K07000	0.003%	HC	-0.0014%	0.006	0.4	ycfP; conserved protein; K07000 (A)
						nrFA; nitrite reductase, formate-dependent, cytochrome; K03385 cytochrome c-552 [EC:1.7.2.2] (A)
K03385	0.008%	HC	-0.0051%	0.008	0.4	

K00096	0.025%	RBD	0.0020%	0.007	0.4	glycerol dehydrogenase; K00096 glycerol-1-phosphate dehydrogenase [NAD(P)] [EC:1.1.1.261] (A)
K00690	0.013%	RBD	0.0007%	0.004	0.3	ycjM; predicted glucosyltransferase; K00690 sucrose phosphorylase [EC:2.4.1.7] (A)
K17318	0.137%	RBD	0.0217%	0.008	0.4	putative aldouronate transport system substrate-binding protein
K17319	0.101%	RBD	0.0146%	0.007	0.4	putative aldouronate transport system permease protein
K17320	0.101%	RBD	0.0146%	0.007	0.4	putative aldouronate transport system permease protein
K09155	0.013%	HC	-0.0047%	0.005	0.4	PAS/PAC sensor protein; K09155 hypothetical protein (A)
K07079	0.068%	RBD	0.0085%	0.006	0.4	aldo/keto reductase; K07079 (A)
K01713	0.002%	HC	0.0023%	0.002	0.3	cyclohexadienyl dehydratase; K01713 cyclohexadienyl dehydratase [EC:4.2.1.51 4.2.1.91] (A)
K02385	0.020%	RBD	0.0025%	0.007	0.4	flbD; flagellar protein FlbD; K02385 flagellar protein FlbD (A)
K08364	0.001%	HC	0.0014%	0.002	0.3	mercuric transport protein periplasmic component precursor MerP; K08364 periplasmic mercuric ion binding protein (A)
K09474	0.006%	HC	-0.0028%	0.001	0.3	acid phosphatase; K09474 acid phosphatase (class A) [EC:3.1.3.2] (A)
K15876	0.006%	HC	-0.0052%	0.004	0.3	NRFH; small subunit of cytochrome c nitrite reductase; K15876 cytochrome c-type protein (A)
K03716	0.014%	RBD	0.0001%	0.010	0.4	DNA repair photolyase; K03716 spore photoproduct lyase [EC:4.1.99.14] (A)
K05792	0.001%	HC	-0.0045%	0.002	0.3	terA; phage inhibition, colicin resistance and tellurite resistance protein; K05792 tellurite resistance protein TerA (A)
K05791	0.001%	HC	0.0014%	0.001	0.3	terZ; phage inhibition, colicin resistance and tellurite resistance protein; K05791 tellurium resistance protein TerZ (A)
K07791	0.006%	HC	-0.0027%	0.008	0.4	dcuA; C4-dicarboxylate antiporter; K07791 anaerobic C4-dicarboxylate transporter DcuA (A)
K07792	0.003%	HC	-0.0032%	0.008	0.4	dcuB; C4-dicarboxylate transporter, anaerobic; DcuS co-sensor; K07792 anaerobic C4 dicarboxylate transporter DcuB (A)
K00113	0.002%	HC	0.0023%	0.001	0.3	glpC; anaerobic sn-glycerol-3-phosphate dehydrogenase, C subunit, 4Fe-4S iron-sulfur cluster; K00113 glycerol-3-phosphate dehydrogenase subunit C [EC:1.1.5.3] (A)
K00895	0.008%	HC	-0.0007%	0.004	0.3	pyrophosphate--fructose-6-phosphate 1-phosphotransferase; K00895 glpB; sn-glycerol-3-phosphate dehydrogenase (anaerobic), membrane anchor subunit (EC:1.1.5.3); K00112 glycerol-3-phosphate dehydrogenase subunit B [EC:1.1.5.3] (A)
K00112	0.002%	HC	0.0023%	0.001	0.3	cynR; transcriptional activator of cyn operon; autorepressor; K11921 LysR family transcriptional regulator (A)
K11921	0.003%	HC	-0.0037%	0.003	0.3	yejM; predicted hydrolase, inner membrane; K07014 (A)
K07014	0.002%	HC	-0.0031%	0.001	0.3	hypothetical protein; K09805 hypothetical protein (A)
K09805	0.002%	HC	-0.0048%	0.000	0.3	yesN; two-component response regulator YesM; K07720 two-component system, response regulator YesN (A)
K07720	0.188%	RBD	0.0212%	0.008	0.4	yceM; predicted oxidoreductase with NAD(P)-binding Rossmann-fold domain; K03810 virulence factor (A)
K03810	0.001%	HC	-0.0043%	0.001	0.3	yesM; two-component sensor histidine kinase YesN; K07718 two-component system, sensor histidine kinase YesM [EC:2.7.13.3] (A)
K07718	0.186%	RBD	0.0218%	0.008	0.4	major facilitator superfamily protein; K06610 MFS transporter, SP family, inositol transporter (A)
K06610	0.001%	HC	-0.0044%	0.002	0.3	Thiol-activated cytolysin; K11031 thiol-activated cytolysin (A)
K11031	0.002%	HC	0.0023%	0.006	0.4	spmB; spore maturation protein B; K06374 spore maturation protein B (A)
K06374	0.023%	RBD	0.0026%	0.009	0.4	spore maturation protein A; K06373 spore maturation protein A (A)
K06373	0.029%	RBD	0.0047%	0.009	0.4	agp; glucose-1-phosphatase/inositol phosphatase (EC:3.1.3.10); K01085 glucose-1-phosphatase [EC:3.1.3.10] (A)
K01085	0.003%	HC	-0.0044%	0.001	0.3	methylaspartate ammonia-lyase C-terminal domain protein; K04835 methylaspartate ammonia-lyase [EC:4.3.1.2] (A)
K04835	0.001%	HC	0.0017%	0.001	0.3	arnE; undecaprenyl phosphate-alpha-L-ara4N exporter; flippase ArnEF subunit; K12962 undecaprenyl phosphate-alpha-L-ara4N flippase subunit ArnE (A)
K12962	0.001%	HC	-0.0044%	0.003	0.3	PANK1, PANK; pantothenate kinase 1 (EC:2.7.1.33); K09680 type II pantothenate kinase [EC:2.7.1.33] (A)
K09680	0.013%	HC	-0.0015%	0.004	0.3	THI1; thiazole biosynthetic enzyme; K03146 thiamine biosynthetic enzyme (A)
K03146	0.002%	HC	-0.0029%	0.003	0.3	NADH:flavin oxidoreductase; K10797 2-enoate reductase [EC:1.3.1.31] (A)
K10797	0.010%	RBD	0.0015%	0.008	0.4	mprA; DNA-binding transcriptional repressor of microcin B17 synthesis and multidrug efflux; K15974 MarR family transcriptional regulator, negative regulator of the multidrug operon emrRAB (A)
K15974	0.001%	HC	0.0014%	0.003	0.3	similar to exo-beta-D-glucosaminidase; K15855 exo-1,4-beta-D-glucosaminidase [EC:3.2.1.165] (A)
K15855	0.001%	HC	-0.0044%	0.001	0.3	nupG; nucleoside transporter; K03289 MFS transporter, NHS family, nucleoside permease (A)
K03289	0.005%	HC	-0.0026%	0.001	0.3	

ID	comment	Sample ID	extraction batch	sequencing run	sequencing coordinate	fastq Files	Forward Primer	Reverse Primer
none	mock-extraction control	exCAD0.f	Al.f	P1	A04	A04-exCFAD-166_514_L001_R1_001.fastq;A04-exCFAD-166_514_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCAD0.f	Bl.f	P1	B04	B04-exCFBD-166_514_L001_R1_001.fastq;B04-exCFBD-166_514_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCAD0.f	Al.f	P1	G08	G08-exCFAD-166_565_L001_R1_001.fastq;G08-exCFAD-166_565_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0C.f	Bl.f	P1	H08	H08-exCFBD-166_573_L001_R1_001.fastq;H08-exCFBD-166_573_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCF1D.f	E2.f	P11	A12	P11.A12-117-exCFE-166_512_L001_R1_001.fastq;P11.A12-117-exCFE-166_512_L001_R2_001.fastq;P11.B04-100-exCFE-166_516_L001_R1_001.fastq;P11.B04-100-exCFE-166_516_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCF1D.f	C2.f	P11	B04	P11.B08-ntc-166_521_L001_R1_001.fastq;P11.B08-ntc-166_521_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCF11.f	NA	P11	B09	P11.B09-ntc-166_521_L001_R1_001.fastq;P11.B09-ntc-166_521_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCF1D.f	B2.f	P11	C02	P11.C02-111-exCFB-166_526_L001_R1_001.fastq;P11.C02-111-exCFB-166_526_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	Al.n	P2	A12	A12-eCA_S86_L001_R1_001.fastq;A12-eCA_S86_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	Bl.n	P2	B12	B12-eCB_S98_L001_R1_001.fastq;B12-eCB_S98_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	C1.n	P2	C12	C12-eCC_S110_L001_R1_001.fastq;C12-eCC_S110_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	D1.n	P2	D12	D12-eCD_S122_L001_R1_001.fastq;D12-eCD_S122_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	E1.n	P2	E12	E12-eCE_S134_L001_R1_001.fastq;E12-eCE_S134_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	G1.n	P2	G10	G10-eCG_S156_L001_R1_001.fastq;G10-eCG_S156_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	H2.n	P3	A12	N-112-eW1-166_512_L001_R1_001.fastq;N-112-eW1-166_512_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	O2.n	P3	B11	O-111-eW1-166_523_L001_R1_001.fastq;O-111-eW1-166_523_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	P2.n	P3	C10	P-110-eW1-166_534_L001_R1_001.fastq;P-110-eW1-166_534_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	Q2.n	P3	D09	Q-109-eW1-166_545_L001_R1_001.fastq;Q-109-eW1-166_545_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	R2.n	P3	E02	R-102-eW1-166_550_L001_R1_001.fastq;R-102-eW1-166_550_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	A2.n	P4	A01	A01-A-101_S1_L001_R1_001.fastq;A01-A-101_S1_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	B2.n	P4	B12	B12-B-112_S24_L001_R1_001.fastq;B12-B-112_S24_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	C2.n	P4	C11	C11-C-111_S35_L001_R1_001.fastq;C11-C-111_S35_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	D2.n	P4	D10	D10-D-110_S46_L001_R1_001.fastq;D10-D-110_S46_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	E2.n	P4	E09	E09-E-109_S57_L001_R1_001.fastq;E09-E-109_S57_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	F2.n	P4	F08	F08-F-108_S68_L001_R1_001.fastq;F08-F-108_S68_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	G2.n	P4	G07	G07-G-107_S79_L001_R1_001.fastq;G07-G-107_S79_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	T2.n	P5	A04	T-104-P9-A04_S76_L001_R1_001.fastq;T-104-P9-A04_S76_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	I2.n	P5	B05	I-105-P5-B05_S17_L001_R1_001.fastq;I-105-P5-B05_S17_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	H2.n	P5	B06	H-106-P9-B06_S90_L001_R1_001.fastq;H-106-P9-B06_S90_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	K2.n	P5	C03	K-103-P5-C03_S27_L001_R1_001.fastq;K-103-P5-C03_S27_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	L2.n	P5	D02	L-102-P5-D02_S38_L001_R1_001.fastq;L-102-P5-D02_S38_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	M2.n	P5	E01	M-101-P5-E01_S49_L001_R1_001.fastq;M-101-P5-E01_S49_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	J2.n	P7	G04	P10-G04-J-104_S40_L001_R1_001.fastq;P10-G04-J-104_S40_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	L2.n	P7	A11	P7-A11-L-111_S26_L001_R1_001.fastq;P7-A11-L-111_S26_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.n	V2.n	P7	B06	P7-B06-V-106_S15_L001_R1_001.fastq;P7-B06-V-106_S15_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCAD1.f	B2.f	H03	H03	P10-H03-FA-103-exCFA_S30_L001_R1_001.fastq;P10-H03-FA-103-exCFA_S30_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	mock-extraction control	exCB0.f	B2.f	P12	C05	C05_111_exCFB_185_GCGTAGTA-TGCGACTAG_L001_R1_001.fastq;C05_111_exCFB_185_GCGTAGTA-TGCGACTAG_L001_R2_001.fastq	CGGTAATYTCAGCTCV	CCGTAATHTHTYAAAT
none	mock-extraction control	exCB0.f	C2.f	P13	B01	P13B01-102-exCFE_S49_L001_R1_001.fastq;P13B01-102-exCFE_S49_L001_R2_001.fastq	CGGTAATYTCAGCTCV	CCGTAATHTHTYAAAT
none	mock-extraction control	exCB0.f	E2.f	P12	C07	C07_117_exCFE_185_TAGCTGCT-TGCGACTAG_L001_R1_001.fastq;C07_117_exCFE_185_TAGCTGCT-TGCGACTAG_L001_R2_001.fastq	CGGTAATYTCAGCTCV	CCGTAATHTHTYAAAT
none	nasal wash solution	saline09	Saline	P2	G11	G11-saline09_S157_L001_R1_001.fastq;G11-saline09_S157_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	no template control	NTC-P1	NA	P1	H09	H09-NTC-166_574_L001_R1_001.fastq;H09-NTC-166_574_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	no template control	NTC-P2	NA	P2	F02	F02-NTC_S136_L001_R1_001.fastq;F02-NTC_S136_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	no template control	NTC-P3	NA	P3	F10	S-110-166_570_L001_R1_001.fastq;S-110-166_570_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	reagent control	elu-P2.n	NA	P2	F07	F07-elu_S141_L001_R1_001.fastq;F07-elu_S141_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	reagent control	elu-P3-1.n	NA	P3	D03	NTC-166_539_L001_R1_001.fastq;NTC-166_539_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	reagent control	elu-P3-2.n	NA	P3	H01	NTC2-166_573_L001_R1_001.fastq;NTC2-166_573_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	reagent control	elu-P4-1.n	NA	P4	E05	E05-E-105_S53_L001_R1_001.fastq;E05-E-105_S53_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	reagent control	elu-P4-2.n	NA	P4	H01	H01-NTC_S85_L001_R1_001.fastq;H01-NTC_S85_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	reagent control	elu-P50.n	NA	P5	C01	NTCo-P9-C01_S69_L001_R1_001.fastq;NTCo-P9-C01_S69_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	reagent control	elu-P5n.n	NA	P5	C02	NTCn-P9-C02_S70_L001_R1_001.fastq;NTCn-P9-C02_S70_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	reagent control	elu-P7n.n	NA	P7	G06	P10-G06-NTCn_S61_L001_R1_001.fastq;P10-G06-NTCn_S61_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	reagent control	elu-P7-1.n	NA	P7	C01	P7-C01-NTC_S4_L001_R1_001.fastq;P7-C01-NTC_S4_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
none	reagent control	elu-P13.f	NA	P13	B06	P13B06-ntc_S54_L001_R1_001.fastq;P13B06-ntc_S54_L001_R2_001.fastq	CGGTAATYTCAGCTCV	CCGTAATHTHTYAAAT
generous donor A	internal standard	GDAD-P1	GDA	P1	A09	A09-GDAD-166_59_L001_R1_001.fastq;A09-GDAD-166_59_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-2-P1	GDA	P1	A10	A10-GDAD-166_510_L001_R1_001.fastq;A10-GDAD-166_510_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-02-P1	GDA	P1	B10	B10-GDAD-03-166_530_L001_R1_001.fastq;B10-GDAD-03-166_530_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-02-P2	GDA	P1	C10	C10-GDAD-01-166_530_L001_R1_001.fastq;C10-GDAD-01-166_530_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-02-P1	GDA	P1	D10	D10-GDAD-001-166_540_L001_R1_001.fastq;D10-GDAD-001-166_540_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-1-P1	GDA	P11	E03	P11.E03-GDA1-166_551_L001_R1_001.fastq;P11.E03-GDA1-166_551_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-2-P1	GDA	P11	F03	P11.F03-GDA2-166_562_L001_R1_001.fastq;P11.F03-GDA2-166_562_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-2-P2	GDA	P2	H09	H09-GD1_S165_L001_R1_001.fastq;H09-GD1_S165_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-3-P3	GDA	P3	H02	GDAD-3-166_574_L001_R1_001.fastq;GDAD-3-166_574_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	exAD03-P3	GDA	P3	H03	GDAD-03-166_575_L001_R1_001.fastq;GDAD-03-166_575_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-3-P4	GDA	P4	H02	H02-GDAD-3_S86_L001_R1_001.fastq;H02-GDAD-3_S86_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-03-P4	GDA	P4	H03	H03-GDAD-03_S87_L001_R1_001.fastq;H03-GDAD-03_S87_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-3-P10	GDA	P7	G07	P10-G07-GDAD-3_S71_L001_R1_001.fastq;P10-G07-GDAD-3_S71_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-03-P10	GDA	P7	G08	P10-G08-GDAD-03_S81_L001_R1_001.fastq;P10-G08-GDAD-03_S81_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-3-P7	GDA	P7	C02	P7-C02-GDAD-3_S16_L001_R1_001.fastq;P7-C02-GDAD-3_S16_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-03-P7	GDA	P7	C03	P7-C03-GDAD-03_S28_L001_R1_001.fastq;P7-C03-GDAD-03_S28_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-3-P10	GDA	P7	H11	P10-H11-GDA1-GDA1_S31_L001_R1_001.fastq;P10-H11-GDA1-GDA1_S31_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-3-P10	GDA	P7	H12	P10-H12-GDA2-GDA2_S42_L001_R1_001.fastq;P10-H12-GDA2-GDA2_S42_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-3-P9	GDA	P9	C03	GDAD-3-P9-C03_S71_L001_R1_001.fastq;GDAD-3-P9-C03_S71_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-3-P9	GDA	P9	C04	GDAD-03-P9-C04_S72_L001_R1_001.fastq;GDAD-03-P9-C04_S72_L001_R2_001.fastq	GTGBCACMGCCGGGTAA	GACTACHVGGGTACTAATCC
generous donor A	internal standard	GDAD-3-P12	GDA	P12	F03	F03_GDA3_185_ACTCGCTA-CGCTAAGA_L001_R1_001.fastq;F03_GDA3_185_ACTCGCTA-CGCTAAGA_L001_R2_001.fastq	CGGTAATYTCAGCTCV	CCGTAATHTHTYAAAT
generous donor A	internal standard	GDAD-3-P13	GDA	P13	F03	P13F03-GDA1_S79_L001_R1_001.fastq;P13F03-GDA1_S79_L001_R2_001.fastq	CGGTAATYTCAGCTCV	CCGTAATHTHTYAAAT
generous donor A	internal standard	GDAD-3-P12	GDA	E03	E03	E03_GDA3_185_ACTCGCTA-CCTAGAGT_L001_R1_001.fastq;E03_GDA3_185_ACTCGCTA-CCTAGAGT_L001_R2_001.fastq	CGGTAATYTCAGCTCV	CCGTAATHTHTYAAAT
generous donor A	internal standard	GDAD-3-P13	GDA	E03	E03	P13E03-GDA2_S73_L001_R1_001.fastq;P13E03-GDA2_S73_L001_R2_001.fastq	CGGTAATYTCAGCTCV	CCGTAATHTHTYAAAT